Edgewood Oncology, Inc.
1 known investors
Find your way into Edgewood Oncology, Inc.
459 people in our graph share verified history with the Edgewood Oncology, Inc. team — schools, employers, funds. One of them is your warm intro.
Cathy Friedmanunlockedknows David N. Cook · together at Harvard University (overlapped)
×7knows the team · via University of California, Berkeley
knows the team · via Seres Therapeutics
×2knows the team · via Stanford University Graduate School of Business
knows the team · via International AIDS Vaccine Initiative
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class treatment candidate for hematologic malignancies and genetically-defined solid tumors. The company focuses on addressing unmet medical needs in cancer treatment.
Founders & leadership
YB
Yinon Ben-NeriahScientific Founder
DN
David N. CookinChief Executive OfficerDavid N. Cook is Chief Executive Officer of Edgewood Oncology, a clinical-stage biotechnology company developing therapies for hematologic malignancies and genetically-defined solid tumors. He has held senior executive roles in biotechnology product development across microbiome therapeutics, vaccines, small molecules, and biologics, with experience spanning discovery research, clinical trials, regulatory affairs, and manufacturing, and has obtained EU marketing authorizations for multiple novel medical products.
ZT
Zung ThaiinChief Medical Officer
Investors · 1
Frequently asked questions
- What does Edgewood Oncology, Inc. do?
- Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class treatment candidate for hematologic malignancies and genetically-defined solid tumors. The company focuses on addressing unmet medical needs in cancer treatment.
- Who founded Edgewood Oncology, Inc.?
- Edgewood Oncology, Inc. was founded by Yinon Ben-Neriah.
- Who are Edgewood Oncology, Inc.'s investors?
- Edgewood Oncology, Inc.'s investors include Alta Partners.